查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1591994

体内 CRO 市场：按类型、GLP 类型、适应症 - 2025-2030 年全球预测

In Vivo CRO Market by Type (Non-Rodent, Rodent), GLP Type (GLP Toxicology, Non-GLP), Indication - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年体内CRO市场规模为44.6亿美元，预计2024年将达到48.7亿美元，复合年增长率为9.75%，预计到2030年将达到85.6亿美元。

体内受託研究机构(CRO) 专门利用活体动物模型向製药、生物技术和相关产业提供委託研究服务。对In Vivo CRO的需求源自于其在临床前开发中的关键作用，提供毒理学、药理学、药物代谢研究等综合服务，帮助客户高效完成I期检查的进行。这些服务的应用包括药物发现、安全性评估和监管提交支持，主要最终用户包括製药公司、生物技术公司和研究机构。市场成长的推动因素包括研发支出的增加、对先进医疗解决方案的需求不断增长，以及透过必要测试获得更准确的资料来减少动物测试的道德驱动力。主要影响因素包括转化研究的技术进步、生物製药管道的扩展以及 CRO 与学术机构之间的合作。最近的发展凸显了个人化医学研究、专门疾病模型和拓展新兴市场的潜在机会。为了抓住这个机会，我们建议投资 CRISPR 和人工智慧驱动的资料分析等最尖端科技，以提高预测的准确性和效率。儘管存在成长潜力，体内 CRO 市场仍面临严格的监管要求、动物福利方面的道德问题以及高昂的营运成本等挑战。为了克服这些问题，公司应该提倡透明的道德实践，投资替代方法来实现 3R（替代、减少、改进），并专注于自动化以简化流程。创新领域包括开发更多与人类相关的模型，例如晶片器官，以及探索人工智慧在预测分析中的作用，以最大限度地减少资源利用率。市场呈现出以快速技术创新和监管环境为特征的动态性质，要求相关人员保持适应性和远见，以维持业务成长并保持竞争力。

主要市场统计
基准年[2023] 44.6亿美元
预测年份 [2024] 48.7亿美元
预测年份 [2030] 85.6亿美元
复合年增长率（%） 9.75%

市场动态：揭示快速发展的体内 CRO 市场的关键市场洞察

供需的动态交互作用正在改变体内 CRO 市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 由于经济利益而增加使用外包服务
    • 增加公共和私人对药物研究的投资
    • 对生物相似药和药物开发的日益关注
  • 市场限制因素
    • 与临床测试过程相关的高成本
  • 市场机会
    • 临床测试流程的全球化
    • 基于专利申请的製药领域竞争状况
  • 市场问题
    • In vivo CRO品管问题

波特五力：驾驭体内 CRO 市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解 In Vivo CRO 市场的外部影响

外部宏观环境因素在塑造 In Vivo CRO 市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助企业预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析：了解体内 CRO 市场的竞争格局

对体内 CRO 市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：体内 CRO 市场供应商绩效评估

FPNV定位矩阵是评估In Vivo CRO市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製体内 CRO 市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，体内 CRO 市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1.市场渗透率：对当前市场环境的详细审查，主要企业的广泛资料，评估他们在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 由于经济利益而增加使用外包服务
      • 增加公共和私营部门对药物研究的投资
      • 生物相似药和药品的开发日益受到关注
    • 抑制因素
      • 与临床测试过程相关的高成本
    • 机会
      • 临床测试流程的全球化
      • 医药领域的专利申请竞争格局
    • 任务
      • 体内CRO的品管问题
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章体内 CRO 市场：依类型

  • 介绍
  • 不囓齿动物
  • 囓齿动物
    • 老鼠
    • 鼠

第 7 章 体内 CRO 市场：依 GLP 类型

  • 介绍
  • GLP
    • 公司内部
    • 外包
  • 非GLP
    • 公司内部
    • 外包

第八章体内 CRO 市场：依适应症分类

  • 介绍
  • 自体免疫/发炎疾病
    • 大肠激躁症
    • 多发性硬化症
    • 骨关节炎
    • 类风湿性关节炎
  • 血癌
  • 中枢神经系统状况
    • 肌萎缩侧索硬化症
    • 癫痫
    • 亨丁顿舞蹈症
    • 肌肉再生
    • 帕金森氏症
    • 中风
    • 脑外伤
  • 糖尿病
  • 肥胖
  • 肿瘤学
  • 疼痛管理
    • 急性疼痛
    • 慢性疼痛
  • 固态肿瘤
    • 患者来源的异种移植物
    • 类似型号
    • 异种移植

第九章美洲体内CRO市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太体内CRO市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲体内CRO市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Charles River Laboratories
  • Crown Bioscience, Inc.
  • Eurofins Scientific SE
  • Evotec SE
  • ICON Plc
  • Labcorp Drug Development
  • Medpace, Inc.
  • MI Bioresearch, Inc.
  • Parexel International Corporation
  • Pharmacology Discovery Services
  • PPD Inc.
  • Syneos Health
  • Syngene International Limited
  • Taconic Biosciences, Inc.
  • WuXi AppTec, Inc.
Product Code: MRR-0D217D5AEEAC

The In Vivo CRO Market was valued at USD 4.46 billion in 2023, expected to reach USD 4.87 billion in 2024, and is projected to grow at a CAGR of 9.75%, to USD 8.56 billion by 2030.

In Vivo Contract Research Organizations (CROs) specialize in providing outsourced research services that involve live animal models to pharmaceutical, biotechnology, and related industries. The necessity of in vivo CROs stems from their critical role in preclinical development, enabling clients to efficiently conduct Phase I trials by offering comprehensive services such as toxicology, pharmacology, and drug metabolism studies. The application of these services spans drug discovery, safety evaluation, and regulatory submission support, with prominent end-users including pharmaceutical companies, biotechnology firms, and research institutions. Market growth is fueled by increased R&D spending, rising demand for advanced healthcare solutions, and the ethical push for reducing animal testing through more precise data from necessary studies. Key influencing factors include technological advancements in translational research, growing biopharmaceutical pipelines, and collaborations between CROs and academia. Recent trends highlight potential opportunities in personalized medicine research, specialized disease models, and expansion into emerging markets. Recommendations for capturing these opportunities involve investing in cutting-edge technologies such as CRISPR and AI-driven data analytics, which enhance predictive accuracy and efficiency. Despite its growth potential, the in vivo CRO market faces challenges like stringent regulatory demands, ethical concerns on animal welfare, and high operational costs. To overcome these, companies should advocate for transparent ethical practices, invest in alternative methods to achieve the 3Rs (Replacement, Reduction, Refinement), and focus on automation to streamline processes. Innovation areas include developing more human-relevant models like organ-on-chips and exploring AI's role in predictive analytics to minimize resource utilization. The market exhibits a dynamic nature characterized by rapid technological changes and regulatory landscapes, necessitating stakeholders to remain adaptive and forward-thinking to sustain business growth and remain competitive.

KEY MARKET STATISTICS
Base Year [2023] USD 4.46 billion
Estimated Year [2024] USD 4.87 billion
Forecast Year [2030] USD 8.56 billion
CAGR (%) 9.75%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving In Vivo CRO Market

The In Vivo CRO Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing usage of outsourcing services due to economic benefits
    • Growing investments in the pharmaceutical research by public and private sectors
    • Rising focus on the development of biosimilar medicines and drugs
  • Market Restraints
    • High cost associated with the clinical trial processes
  • Market Opportunities
    • Globalization of clinical trial processes
    • Competitive landscape in the pharmaceutical sector with patent applications
  • Market Challenges
    • Issues related to quality control in In vivo CROs

Porter's Five Forces: A Strategic Tool for Navigating the In Vivo CRO Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the In Vivo CRO Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the In Vivo CRO Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the In Vivo CRO Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the In Vivo CRO Market

A detailed market share analysis in the In Vivo CRO Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the In Vivo CRO Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the In Vivo CRO Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the In Vivo CRO Market

A strategic analysis of the In Vivo CRO Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the In Vivo CRO Market, highlighting leading vendors and their innovative profiles. These include Charles River Laboratories, Crown Bioscience, Inc., Eurofins Scientific SE, Evotec SE, ICON Plc, Labcorp Drug Development, Medpace, Inc., MI Bioresearch, Inc., Parexel International Corporation, Pharmacology Discovery Services, PPD Inc., Syneos Health, Syngene International Limited, Taconic Biosciences, Inc., and WuXi AppTec, Inc..

Market Segmentation & Coverage

This research report categorizes the In Vivo CRO Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Non-Rodent and Rodent. The Rodent is further studied across Mice and Rats.
  • Based on GLP Type, market is studied across GLP Toxicology and Non-GLP. The GLP Toxicology is further studied across In House and Outsourcing. The Non-GLP is further studied across In House and Outsourcing.
  • Based on Indication, market is studied across Autoimmune/inflammation conditions, Blood Cancer, CNS conditions, Diabetes, Obesity, Oncology, Pain management, and Solid Tumor. The Autoimmune/inflammation conditions is further studied across Irritable Bowel Syndrome, Multiple Sclerosis, Osteoarthritis, and Rheumatoid Arthritis. The CNS conditions is further studied across ALS, Epilepsy, Huntington's Disease, Muscle Regeneration, Parkinson's Disease, Stroke, and Traumatic Brain Injury. The Pain management is further studied across Acute Pain and Chronic Pain. The Solid Tumor is further studied across Patient-derived Xenograft, Syngeneic Model, and Xenograft.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing usage of outsourcing services due to economic benefits
      • 5.1.1.2. Growing investments in the pharmaceutical research by public and private sectors
      • 5.1.1.3. Rising focus on the development of biosimilar medicines and drugs
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with the clinical trial processes
    • 5.1.3. Opportunities
      • 5.1.3.1. Globalization of clinical trial processes
      • 5.1.3.2. Competitive landscape in the pharmaceutical sector with patent applications
    • 5.1.4. Challenges
      • 5.1.4.1. Issues related to quality control in In vivo CROs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. In Vivo CRO Market, by Type

  • 6.1. Introduction
  • 6.2. Non-Rodent
  • 6.3. Rodent
    • 6.3.1. Mice
    • 6.3.2. Rats

7. In Vivo CRO Market, by GLP Type

  • 7.1. Introduction
  • 7.2. GLP Toxicology
    • 7.2.1. In House
    • 7.2.2. Outsourcing
  • 7.3. Non-GLP
    • 7.3.1. In House
    • 7.3.2. Outsourcing

8. In Vivo CRO Market, by Indication

  • 8.1. Introduction
  • 8.2. Autoimmune/inflammation conditions
    • 8.2.1. Irritable Bowel Syndrome
    • 8.2.2. Multiple Sclerosis
    • 8.2.3. Osteoarthritis
    • 8.2.4. Rheumatoid Arthritis
  • 8.3. Blood Cancer
  • 8.4. CNS conditions
    • 8.4.1. ALS
    • 8.4.2. Epilepsy
    • 8.4.3. Huntington's Disease
    • 8.4.4. Muscle Regeneration
    • 8.4.5. Parkinson's Disease
    • 8.4.6. Stroke
    • 8.4.7. Traumatic Brain Injury
  • 8.5. Diabetes
  • 8.6. Obesity
  • 8.7. Oncology
  • 8.8. Pain management
    • 8.8.1. Acute Pain
    • 8.8.2. Chronic Pain
  • 8.9. Solid Tumor
    • 8.9.1. Patient-derived Xenograft
    • 8.9.2. Syngeneic Model
    • 8.9.3. Xenograft

9. Americas In Vivo CRO Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific In Vivo CRO Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa In Vivo CRO Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Charles River Laboratories
  • 2. Crown Bioscience, Inc.
  • 3. Eurofins Scientific SE
  • 4. Evotec SE
  • 5. ICON Plc
  • 6. Labcorp Drug Development
  • 7. Medpace, Inc.
  • 8. MI Bioresearch, Inc.
  • 9. Parexel International Corporation
  • 10. Pharmacology Discovery Services
  • 11. PPD Inc.
  • 12. Syneos Health
  • 13. Syngene International Limited
  • 14. Taconic Biosciences, Inc.
  • 15. WuXi AppTec, Inc.

LIST OF FIGURES

  • FIGURE 1. IN VIVO CRO MARKET RESEARCH PROCESS
  • FIGURE 2. IN VIVO CRO MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL IN VIVO CRO MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL IN VIVO CRO MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL IN VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL IN VIVO CRO MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL IN VIVO CRO MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL IN VIVO CRO MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL IN VIVO CRO MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS IN VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS IN VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES IN VIVO CRO MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES IN VIVO CRO MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. IN VIVO CRO MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. IN VIVO CRO MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. IN VIVO CRO MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL IN VIVO CRO MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL IN VIVO CRO MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. IN VIVO CRO MARKET DYNAMICS
  • TABLE 7. GLOBAL IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL IN VIVO CRO MARKET SIZE, BY NON-RODENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL IN VIVO CRO MARKET SIZE, BY RODENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL IN VIVO CRO MARKET SIZE, BY MICE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL IN VIVO CRO MARKET SIZE, BY RATS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL IN VIVO CRO MARKET SIZE, BY IN HOUSE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL IN VIVO CRO MARKET SIZE, BY OUTSOURCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL IN VIVO CRO MARKET SIZE, BY NON-GLP, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL IN VIVO CRO MARKET SIZE, BY IN HOUSE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL IN VIVO CRO MARKET SIZE, BY OUTSOURCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL IN VIVO CRO MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL IN VIVO CRO MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL IN VIVO CRO MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL IN VIVO CRO MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL IN VIVO CRO MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL IN VIVO CRO MARKET SIZE, BY ALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL IN VIVO CRO MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL IN VIVO CRO MARKET SIZE, BY HUNTINGTON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL IN VIVO CRO MARKET SIZE, BY MUSCLE REGENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL IN VIVO CRO MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL IN VIVO CRO MARKET SIZE, BY STROKE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL IN VIVO CRO MARKET SIZE, BY TRAUMATIC BRAIN INJURY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL IN VIVO CRO MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL IN VIVO CRO MARKET SIZE, BY OBESITY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL IN VIVO CRO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL IN VIVO CRO MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL IN VIVO CRO MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL IN VIVO CRO MARKET SIZE, BY PATIENT-DERIVED XENOGRAFT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL IN VIVO CRO MARKET SIZE, BY SYNGENEIC MODEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL IN VIVO CRO MARKET SIZE, BY XENOGRAFT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 77. BRAZIL IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. CANADA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 87. CANADA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. CANADA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 89. CANADA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 90. CANADA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 92. MEXICO IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. MEXICO IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 94. MEXICO IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. MEXICO IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 96. MEXICO IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 97. MEXICO IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. MEXICO IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 99. MEXICO IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 100. MEXICO IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 101. MEXICO IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED STATES IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED STATES IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED STATES IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED STATES IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED STATES IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. UNITED STATES IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 109. UNITED STATES IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 110. UNITED STATES IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 111. UNITED STATES IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 112. UNITED STATES IN VIVO CRO MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 124. AUSTRALIA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 126. AUSTRALIA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 128. AUSTRALIA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. AUSTRALIA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 132. AUSTRALIA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 134. CHINA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. CHINA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 136. CHINA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. CHINA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 138. CHINA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 139. CHINA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. CHINA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 141. CHINA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 142. CHINA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 143. CHINA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 144. INDIA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. INDIA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 146. INDIA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. INDIA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 148. INDIA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 149. INDIA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 150. INDIA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 151. INDIA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 152. INDIA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 153. INDIA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 154. INDONESIA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. INDONESIA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 156. INDONESIA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. INDONESIA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 158. INDONESIA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 159. INDONESIA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. INDONESIA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 161. INDONESIA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 162. INDONESIA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 163. INDONESIA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 164. JAPAN IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. JAPAN IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 166. JAPAN IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. JAPAN IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 168. JAPAN IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 169. JAPAN IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 170. JAPAN IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 171. JAPAN IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 172. JAPAN IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 173. JAPAN IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 174. MALAYSIA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. MALAYSIA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 176. MALAYSIA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. MALAYSIA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 178. MALAYSIA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 179. MALAYSIA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. MALAYSIA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 181. MALAYSIA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 182. MALAYSIA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 183. MALAYSIA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 184. PHILIPPINES IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 186. PHILIPPINES IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 188. PHILIPPINES IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 190. PHILIPPINES IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 192. PHILIPPINES IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 193. PHILIPPINES IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 194. SINGAPORE IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. SINGAPORE IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 196. SINGAPORE IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. SINGAPORE IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 198. SINGAPORE IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 199. SINGAPORE IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 200. SINGAPORE IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 201. SINGAPORE IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 202. SINGAPORE IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 203. SINGAPORE IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 212. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 213. SOUTH KOREA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 214. TAIWAN IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. TAIWAN IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 216. TAIWAN IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. TAIWAN IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 218. TAIWAN IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 219. TAIWAN IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 220. TAIWAN IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 221. TAIWAN IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 222. TAIWAN IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 223. TAIWAN IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 224. THAILAND IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. THAILAND IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 226. THAILAND IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. THAILAND IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 228. THAILAND IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 229. THAILAND IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 230. THAILAND IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 231. THAILAND IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 232. THAILAND IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 233. THAILAND IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 234. VIETNAM IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. VIETNAM IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 236. VIETNAM IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. VIETNAM IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 238. VIETNAM IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 239. VIETNAM IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 240. VIETNAM IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 241. VIETNAM IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 242. VIETNAM IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 243. VIETNAM IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 255. DENMARK IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. DENMARK IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 257. DENMARK IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. DENMARK IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 259. DENMARK IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 260. DENMARK IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 261. DENMARK IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 262. DENMARK IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 263. DENMARK IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 264. DENMARK IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 265. EGYPT IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. EGYPT IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 267. EGYPT IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. EGYPT IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 269. EGYPT IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 270. EGYPT IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 271. EGYPT IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 272. EGYPT IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 273. EGYPT IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 274. EGYPT IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 275. FINLAND IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. FINLAND IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 277. FINLAND IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 278. FINLAND IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 279. FINLAND IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 280. FINLAND IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 281. FINLAND IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 282. FINLAND IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 283. FINLAND IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 284. FINLAND IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 285. FRANCE IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 286. FRANCE IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 287. FRANCE IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 288. FRANCE IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 289. FRANCE IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 290. FRANCE IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 291. FRANCE IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 292. FRANCE IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 293. FRANCE IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 294. FRANCE IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 295. GERMANY IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 296. GERMANY IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 297. GERMANY IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 298. GERMANY IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 299. GERMANY IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 300. GERMANY IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 301. GERMANY IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 302. GERMANY IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 303. GERMANY IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 304. GERMANY IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 305. ISRAEL IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 306. ISRAEL IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 307. ISRAEL IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 308. ISRAEL IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 309. ISRAEL IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 310. ISRAEL IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 311. ISRAEL IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 312. ISRAEL IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 313. ISRAEL IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 314. ISRAEL IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 315. ITALY IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 316. ITALY IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 317. ITALY IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 318. ITALY IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 319. ITALY IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 320. ITALY IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 321. ITALY IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 322. ITALY IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 323. ITALY IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 324. ITALY IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 325. NETHERLANDS IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 326. NETHERLANDS IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 327. NETHERLANDS IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 328. NETHERLANDS IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 329. NETHERLANDS IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 330. NETHERLANDS IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 331. NETHERLANDS IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 332. NETHERLANDS IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 333. NETHERLANDS IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 334. NETHERLANDS IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 335. NIGERIA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 336. NIGERIA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 337. NIGERIA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 338. NIGERIA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 339. NIGERIA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 340. NIGERIA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 341. NIGERIA IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 342. NIGERIA IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 343. NIGERIA IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 344. NIGERIA IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 345. NORWAY IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 346. NORWAY IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 347. NORWAY IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 348. NORWAY IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 349. NORWAY IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 350. NORWAY IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 351. NORWAY IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 352. NORWAY IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 353. NORWAY IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 354. NORWAY IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 355. POLAND IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 356. POLAND IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 357. POLAND IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 358. POLAND IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 359. POLAND IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 360. POLAND IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 361. POLAND IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 362. POLAND IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 363. POLAND IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 364. POLAND IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 365. QATAR IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 366. QATAR IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 367. QATAR IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 368. QATAR IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 369. QATAR IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)
  • TABLE 370. QATAR IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 371. QATAR IN VIVO CRO MARKET SIZE, BY AUTOIMMUNE/INFLAMMATION CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 372. QATAR IN VIVO CRO MARKET SIZE, BY CNS CONDITIONS, 2018-2030 (USD MILLION)
  • TABLE 373. QATAR IN VIVO CRO MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 374. QATAR IN VIVO CRO MARKET SIZE, BY SOLID TUMOR, 2018-2030 (USD MILLION)
  • TABLE 375. RUSSIA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 376. RUSSIA IN VIVO CRO MARKET SIZE, BY RODENT, 2018-2030 (USD MILLION)
  • TABLE 377. RUSSIA IN VIVO CRO MARKET SIZE, BY GLP TYPE, 2018-2030 (USD MILLION)
  • TABLE 378. RUSSIA IN VIVO CRO MARKET SIZE, BY GLP TOXICOLOGY, 2018-2030 (USD MILLION)
  • TABLE 379. RUSSIA IN VIVO CRO MARKET SIZE, BY NON-GLP, 2018-2030 (USD MILLION)

TA